FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
EVNIN ANTHONY B
  2. Issuer Name and Ticker or Trading Symbol
AVEO PHARMACEUTICALS, INC. [AVEO] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET		 3. Date of Earliest Transaction (Month/Day/Year)
01/19/2023
(Street)

BOSTON, MA 02108		 4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/19/2023   D   41,841 D $ 15 (1) 0 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 25.9 01/19/2023   D     1,250   (2) 05/29/2023 Common Stock 1,250 (2) 0 D  
Stock Option (Right to Buy) $ 15.7 01/19/2023   D     1,250   (2) 06/19/2024 Common Stock 1,250 (2) 0 D  
Stock Option (Right to Buy) $ 16.1 01/19/2023   D     2,515   (2) 04/02/2025 Common Stock 2,515 (2) 0 D  
Stock Option (Right to Buy) $ 20 01/19/2023   D     2,000   (2) 05/28/2025 Common Stock 2,000 (2) 0 D  
Stock Option (Right to Buy) $ 9.2 01/19/2023   D     6,402   (2) 05/26/2026 Common Stock 6,402 (2) 0 D  
Stock Option (Right to Buy) $ 7 01/19/2023   D     7,785   (2) 06/21/2027 Common Stock 7,785 (2) 0 D  
Stock Option (Right to Buy) $ 22.7 01/19/2023   D     4,000   (2) 06/17/2028 Common Stock 4,000 (2) 0 D  
Stock Option (Right to Buy) $ 7.6 01/19/2023   D     4,000   (2) 06/11/2029 Common Stock 4,000 (2) 0 D  
Stock Option (Right to Buy) $ 7.52 01/19/2023   D     4,000   (2) 06/09/2030 Common Stock 4,000 (2) 0 D  
Stock Option (Right to Buy) $ 7.27 01/19/2023   D     12,500   (2) 06/08/2031 Common Stock 12,500 (2) 0 D  
Stock Option (Right to Buy) $ 4.27 01/19/2023   D     22,500   (2) 06/06/2032 Common Stock 22,500 (2) 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
EVNIN ANTHONY B
C/O AVEO PHARMACEUTICALS, INC.
30 WINTER STREET
BOSTON, MA 02108		   X      

Signatures

 /s/ Danielle V. Holland, attorney in fact   01/19/2023
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.
(2) This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
 
Remarks:
On January 19, 2022, pursuant to the Agreement and Plan of Merger (as it may be amended from time to time, referred to as the "Merger Agreement"), by and among LG Chem, Ltd. ("Parent"), Acacia acquisition Sub, Inc. ("Merger Sub") and AVEO Pharmaceuticals, Inc. (the "Company"), dated as of October 18, 2022, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of the Company's common stock automatically converted into the right to receive $15.00 per share in cash (the "Merger Consideration").

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.